Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - PROLOR Biotech, Inc.v330152_ex99-1.htm

 


 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported): December 12, 2012

 

 

PROLOR BIOTECH, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Nevada

000-52691

20-0854033

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

 

 

7 Golda Meir Street

Weizmann Science Park

Nes-Ziona, Israel 74140

(Address of Principal Executive Office)

 

 

Registrant’s telephone number, including area code (866) 644-7811

 

(Former Name or Former Address, if Changed Since Last Report)

 


  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 7.01.Regulation FD Disclosure.

 

On December 12, 2012, PROLOR Biotech, Inc., a Nevada corporation (the “Company”), will deliver a corporate presentation at the Oppenheimer 23rd Annual Healthcare Conference at 9:25 a.m. EST, during which the Company will present certain slides (the “Presentation”). A copy of the Presentation is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 7.01.

 

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended.

 

ITEM 9.01.Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
Number

 

Description

99.1   Slide Presentation

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  prolor biotech, inc.
     
Date:  December 12, 2012 By:  /s/ Shai Novik
    Shai Novik
    President

 

 
 

 

EXHIBIT INDEX

 

Exhibit
Number

 

Description

99.1   Slide Presentation